AIM ImmunoTech Inc. (AIM) community

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30

$0.14−0.01 (-3.36%)

Close on Nov 13, 2026Market cap $4.37MP/E –Yield –

Community

Notes and questions about AIM ImmunoTech from other investors

No posts about AIM yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Compare: AIM vs INMB · AIM vs ABPO · AIM vs ARTV · AIM vs ATYR · AIM vs HIND

Company	Revenue	Growth
HIND	$153.10K	-55.6%
AIM	$91.00K	-18.8%
INMB	–	–
ABPO	–	–
ARTV	–	–
ATYR	–	–

Company

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Held by institutions: 3.8%
Auditor: BDO USA, P.C.
SEC CIK: 946644

Advertisement
300 × 250

See a number that looks wrong?